S&P Futures
3,948.00 -30.00 (-0.75%) Dow Futures
32,017.00 -302.00 (-0.93%) Nasdaq Futures
12,804.50 -49.50 (-0.39%) Russell 2000 Futures
1,712.50 -20.00 (-1.15%) Crude Oil
67.25 -2.71 (-3.87%) Gold
1,994.00 -1.90 (-0.10%)
Journey Medical Corporation (DERM)
Chart Events
Performance Outlook
| Previous Close | 1.5200 |
| Open | 1.4500 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 800 |
| Day's Range | 1.3100 - 1.5000 |
| 52 Week Range | 1.0500 - 5.1200 |
| Volume | |
| Avg. Volume | 40,530 |
| Market Cap | 24.517M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1580 |
| Earnings Date | Aug 09, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.33 |
- GlobeNewswire
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023
Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ETSCOTTSDALE, Ariz., March 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2022 financial
- GlobeNewswire
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Subjects completed 16-week treatment with no significant safety issues Topline results expected in the first half of 2023 SCOTTSDALE, Ariz., March 16, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced completion of treatment in the Phase 1 clinical trial assessing the im
- GlobeNewswire
Journey Medical Corporation to Participate in the 35th Annual ROTH Conference
SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 35th Annual ROTH Conference, which is being held March 12-14, 2023. More specifically, Claude Maraoui, President and Chief Executive Officer, will partc
